Cite
HARVARD Citation
Seto, T. et al. (2022). Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). Journal for immunotherapy of cancer. 10 (2), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Seto, T. et al. (2022). Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). Journal for immunotherapy of cancer. 10 (2), p. . [Online].